QUICK ANSWER · AEO / GEO
A mitochondria-targeted peptide with product- and indication-specific regulatory status; approval in one context does not support wellness claims.
ENTITY FACTS
What should readers identify first?
What remains unknown?
- whether the intermediate knee-strength endpoint translates into durable patient-important benefit
- results of the required randomized confirmatory Barth-syndrome trial NCT07531251, which was listed as not yet recruiting in the record last posted 6 May 2026
- benefit in children under 30 kg and several renal-impairment contexts
- long-term rare adverse events in a broader and more diverse population
- efficacy for other mitochondrial, ophthalmic, neurologic or cardiovascular diseases
- current marketing-authorisation status outside the United States where direct approval records remain unverified
What limits these conclusions?
- The approved Barth-syndrome evidence base is extremely small: 12 male participants, mostly White, at one U.S. site. Randomized primary endpoints were negative; the approval relied on an intermediate muscle-strength endpoint observed during a nonrandomized open-label extension. Accelerated approval requires confirmation. Evidence from other diseases is mixed or negative and cannot be transferred to Barth syndrome or wellness claims.
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf
- https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome
- https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-forzinity
- https://www.fda.gov/drugs/accelerated-approval-program/ongoing-non-malignant-hematological-neurological-and-other-disorder-indications-accelerated
- https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/215244Orig1s000Approv.pdf
- https://clinicaltrials.gov/study/NCT07531251
- https://pubmed.ncbi.nlm.nih.gov/33077895/
- https://pubmed.ncbi.nlm.nih.gov/37268435/
- https://pubmed.ncbi.nlm.nih.gov/39605874/
- https://clinicaltrials.gov/study/NCT03323749
- https://clinicaltrials.gov/study/NCT03891875
- https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2430
- https://products.mhra.gov.uk/
FAQ · ANSWER ENGINE
Frequently asked questions
What is Elamipretide?
Elamipretide is described pharmacologically as Mitochondrial cardiolipin-binding tetrapeptide. A mitochondria-targeted peptide with product- and indication-specific regulatory status; approval in one context does not support wellness claims.
Does Elamipretide have strong evidence?
PrimeCoreBio records Evidence Grade A. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is Elamipretide approved everywhere?
No global conclusion should be inferred. PrimeCore Class A must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.